microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma

Diagnostic Pathology

Jianjian Zheng²  Peihong Dong¹  Bicheng Chen²  Zhongqiu Lu³  Fujun Yu¹ 

[1] Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, No.2 FuXue lane, Wenzhou 325000, Zhejiang, People’s Republic of China;Key Laboratory of Surgery, The First Affiliated Hospital of Wenzhou Medical University, No.2 FuXue lane, Wenzhou 325000, People’s Republic of China;Emergency Department, The First Affiliated Hospital of Wenzhou Medical University, No.2 FuXue lane, Wenzhou 325000, Zhejiang, People’s Republic of China

关键词: Serum;    Biomarker;    Hepatocellular carcinoma;    microRNA-150;   

Others  :  1225937
DOI  :  10.1186/s13000-015-0369-y

 received in 2015-03-20, accepted in 2015-07-15,  发布年份 2015

【 摘 要 】

Background

Chronic hepatitis B virus (HBV) infection is a known major etiological factor for hepatocellular carcinoma (HCC) development. Alpha-fetoprotein (AFP) is widely used to detect primary HCC, whereas its sensitivity and specificity are not satisfying. Recently, circulating microRNAs (miRNAs) have been reported to be promising biomarkers for diagnosing and monitoring cancers. This study was conducted to detect the application of serum miR-150 in the diagnosis and prognosis of HBV-related HCC.

Methods

The expression of miR-150 was evaluated using a real-time quantitative RT-PCR in 350 serum samples (120 samples from controls, 110 from chronic hepatitis B (CHB) patients and 120 samples from HCC patients.

Results

Serum miR-150 levels were significantly reduced in HCC patients, compared with healthy controls (P < 0.0001) and CHB patients (P < 0.0001). Serum miR-150 levels were increased after surgical operation (P < 0.0001) and decreased after tumor recurrence (P < 0.0001). Receiver operating characteristic curve (ROC) analyses suggested that serum miR-150 had significant diagnostic value for HBV-related HCC. It yielded an area under the curve (AUC) of ROC of 0.931 with 82.5 % sensitivity and 83.7 % specificity in discriminating HCC from healthy controls, and an AUC of ROC of 0.881 with 79.1 % sensitivity and 76.5 % specificity in discriminating HCC from CHB patients. Moreover, Kaplan-Meier curve analysis revealed that HCC patients with lower serum miR-150 had a significantly shortened overall survival (P < 0.0001). Univariate and Multivariable Cox regression analysis indicated that serum miR-150 level was an independent risk factor for overall survival (P < 0.0001 and P = 0.015, respectively).

Conclusions

Serum miR-150 can serve as a non-invasive biomarker for the diagnosis and prognosis of HCC patients.

【 授权许可】

   
2015 Yu et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134:1752-63.
• [2]Xie Y, Yao Q, Butt AM, Guo J, Tian Z, Bao X et al.. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther. 2014; 15:1248-55.
• [3]Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B et al.. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008; 14:470-7.
• [4]Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-97.
• [5]Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J. 2008; 14:1-6.
• [6]He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5:522-31.
• [7]Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005; 15:563-8.
• [8]Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W et al.. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006; 99:671-8.
• [9]Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y et al.. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009; 69:1135-42.
• [10]Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al.. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103:2257-61.
• [11]Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6:259-69.
• [12]Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al.. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105:10513-8.
• [13]Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011; 6:e28486.
• [14]Zheng J, Lin Z, Dong P, Lu Z, Gao S, Chen X et al.. Activation of hepatic stellate cells is suppressed by microRNA-150. Int J Mol Med. 2013; 32:17-24.
• [15]Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al.. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008; 40:43-50.
• [16]Zhang J, Luo N, Luo Y, Peng Z, Zhang T, Li S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol. 2012; 40:747-56.
• [17]Yin Q, Sun X, Yang G, Li X, Wu M, Zhao J. Increased expression of microRNA-150 is associated with poor prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 2015; 8:842-6.
• [18]Jin M, Yang Z, Ye W, Xu H, Hua X. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. PLoS One. 2014; 9:e103965.
• [19]2004 guidelines for surgical treatment of primary hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2005; 13:329-30.
• [20]Qin S. Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition). Chin Clin Oncol. 2012; 1:10.
• [21]Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60:646-9.
• [22]Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19:329-38.
• [23]Yao J, Liang L, Huang S, Ding J, Tan N, Zhao Y et al.. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 2010; 51:846-56.
• [24]Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012; 57:2910-6.
• [25]Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM et al.. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009; 7:350-91.
• [26]Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011; 45:355-60.
• [27]Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci. 2011; 56:2009-16.
• [28]Visone R, Petrocca F, Croce CM. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology. 2008; 135:1866-9.
• [29]Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T et al.. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009; 114:5331-41.
• [30]Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al.. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18:997-1006.
• [31]Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N et al.. Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3:e3148.
• [32]Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE et al.. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011; 4:575-86.
• [33]Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010; 127:118-26.
• [34]Di Masi A, Viganotti M, Antoccia A, Magrelli A, Salvatore M, Azzalin G et al.. Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta - catenin pathway, microRNA expression and protein expression profile. Cell Mol Biol (Noisy-le-Grand). 2010; 56 Suppl:OL1299-317.
• [35]Varnholt H. The role of microRNAs in primary liver cancer. Ann Hepatol. 2008; 7:104-13.
• [36]Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008; 359:1486-500.
• [37]Johnson PJ, Melia WM, Palmer MK, Portmann B, Williams R. Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma. Br J Cancer. 1981; 44:502-5.
• [38]Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000; 89:2266-73.
• [39]Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J et al.. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013; 49:3442-9.
• [40]EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56:908-43.
• [41]Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis. 2005; 25:133-42.